Skip to main content
Equibles
CNMD logo

CNMD · CONMED Corp

Track CNMD — free

Use CNMD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CNMD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$50.59 +0.11 (+0.22%) At close · Nov 13
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.51B
Shares
29.80M
Volume · Nov 13 189.73K Avg daily vol (3M) 361.46K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$50.59 Open$51.45 Day$50.40–51.45 52W close$32.11–53.66 Avg vol 30d410K Short int1.9M · 6.2% of shares · 4.3d Short vol86% Last earningsOct 28, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 28

Up next

Next earnings call
Jan 27, 2027 Est · unconfirmed · in 10 wks
Q2 2026 earnings call transcript
call held Jul 29, 2026
Play latest call

Latest documents

2026
Oct 28
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3

CONMED reported results for the nine months ended September 30, 2026: net sales of $996.1 million, down 0.5%, and net income of $56.7 million; gross margin rose to 57.2%. Operating cash flow was $100.0 million.

Revenue $335.56M ▼ 0.7% Net income $19.8M ▲ 592.4% Diluted EPS $0.66 ▲ 633.3%
Read from the MD&A section
Oct 28
Current report 8-K
Financial results

CONMED Corporation posted third-quarter sales of $335.6 million, down 0.7% year-over-year, and organic constant-currency growth of 6.7%. Diluted EPS was $0.66 and adjusted diluted EPS was $1.04; full-year sales guidance is $1,360 million–$1,366 million and adjusted diluted EPS is $4.54–$4.61.

Jul 29
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $343.49M ▲ 0.3% Net income $23.07M ▲ 7.7% Diluted EPS $0.77 ▲ 11.6%
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.37B
Trailing 12 months
Net income (TTM)
$73.43M
Trailing 12 months
Revenue growth YoY
-0.7%
Year over year
Operating margin
9.9%
Trailing 12 months
P / E (TTM)
20.9
Trailing earnings · reciprocal yield 4.8%
FCF yield
8.8%
TTM · current market cap
Return on invested capital
5.2%
Trailing 12 months
Net cash
−$767.89M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-3.0%
Year over year · fewer shares
Price change (1Y)
+16.9%
Trailing year
Short interest
6.2%
Latest settlement · 4.3 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲5.8% $345.94M $33.75M '24 Q4* ▲2.9% $321.26M $6.04M '25 Q1 ▲3.1% $342.35M $21.42M '25 Q2 ▲6.7% $337.93M $2.86M '25 Q3 ▲7.9% $373.20M $16.74M '25 Q4* ▼1.3% $317.05M $13.83M '26 Q1 ▲0.3% $343.49M $23.07M '26 Q2 LATEST ▼0.7% $335.56M $19.80M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q2 FY26 earnings call · Jul 29, 2026
Q2 FY26

TL;DR. CONMED reported Q2 organic constant-currency sales growth of 6.0% and adjusted EPS of $1.38 (up 20%), aided by a $0.21 tariff-refund benefit, while raising full-year adjusted EPS guidance to $4.48–$4.60 but narrowing the top end of organic growth guidance to 5–6% from 5–6.5%.

Bullish
  • + Q2 adjusted EPS of $1.38, up 20% YoY, beating the high end of guidance (including a $0.21 tariff refund).
  • + Raised full-year 2026 adjusted EPS guidance to $4.48–$4.60 from $4.30–$4.45.
  • + Q2 organic constant-currency sales growth of 6.0% modestly exceeded the high end of expectations.
Bearish
  • − Narrowed top end of full-year organic constant-currency sales growth guidance to 5–6% from 5–6.5%, citing a more measured pace of H2 improvement.
  • − Raised full-year adjusted interest expense assumption to ~$33M from prior $25M–$27M.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +21%
above
Price vs 50-day avg +7%
above
RSI (14) 57
neutral
MACD trend Positive
52-week position 86%
near high
Volume (OBV) Bearish div.
distributing
Momentum
relative strength
Very Strong
1-month return +8%
trailing
6-month return +40%
trailing
YTD return +25%
this year
Relative strength +40%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $47 › 200d $42 — 50d above 200d
Institutional flow Distributing
230 of 248 funds reported for Sep 30 · net -836.9K sh shares · +37 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
6.24% of shares out · ▼ -2.7% MoM · 4.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
248 holders — mid 3-yr range
Squeeze score 67
elevated · 0–100
Fundamentals
Strong
Revenue growth +5%
Y/Y
Gross margin 55%
contracting
EPS growth −64%
Y/Y
Free cash flow $150.9M
Valuation P/E 20.9
below peers
Buyback $112.6M
remaining
Balance sheet $794.1M
net debt
Quant / Vol
risk profile
High
Volatility 47%
annualized · 1-yr
Max drawdown −30%
past year
ATR 4.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 5 of last 7
Latest guidance · from the 8-K filed Jul 29, 2026
Adjusted Diluted EPS · Twelve Months Ending December 31, 2026 Non-GAAP Raised $4.48 – $4.60
Apr 29, 2026 $4.30 – $4.45 changed to Jul 29, 2026 $4.48 – $4.60
Previous outlook earlier release · from the 8-K filed Apr 29, 2026

Still-open targets the latest release did not restate under the same label.

Reported revenue · full-year 2026 $1.35B – $1.38B
Prior guidance period ended · from the Earnings Call filed Apr 29, 2026
Reported revenue · Q2 2026 $336M – $340M
Adjusted EPS · Q2 2026 $1.09 – $1.14
Guided vs delivered · last 7 settled
Reported revenue Q2 2026
guided $336M – $340M
$343.49M Beat +1.6%
Full-year reported revenue full-year 2025
guided $1.37B – $1.37B
$1.37B Beat +0.5%
Full year reported revenue full year
guided $1.31B – $1.32B
$1.31B In line
Revenue full-year 2023
guided $1.24B – $1.26B
$1.24B In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+21% Bullish
Price vs 50-day avg
+7% Bullish
RSI (14)
57 Neutral
MACD trend
Positive Bullish
52-week position
86% Bullish
Volume (OBV)
Bearish div. Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $47 › 200d $42 — 50d above 200d
Institutional flow Distributing
230 of 248 funds reported for Sep 30 · net -836.9K sh shares · +37 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
6.24% of shares out · ▼ -2.7% MoM · 4.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
248 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $32 Now $51 · 86% Range high $54
vs 200-day avg +21% vs 50-day avg +7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted diluted earnings per share non-GAAP $1.38 Second Quarter 2026 —
Adjusted gross profit % non-GAAP 58.5% Six Months Ended June 30, 2026 —
Capital Products As Reported 6.6% Six Months Ended June 30, 2026 —
Capital Products Constant Currency non-GAAP 5.4% Six Months Ended June 30, 2026 —
Domestic sales growth, Organic non-GAAP 2.5% Second Quarter 2026 —
EBITDA non-GAAP 102.53M Six Months Ended June 30, 2026 —
EBITDA Margin non-GAAP 15.5% Six Months Ended June 30, 2026 —
International sales growth, as reported 7.9% Six Months Ended June 30, 2026 —
International sales growth, Constant Currency non-GAAP 8.9% Second Quarter 2026 —
International sales growth, Organic Constant Currency non-GAAP 5.8% Six Months Ended June 30, 2026 —
Net Sales Growth, Organic Constant Currency non-GAAP 6% Second Quarter 2026 —
Sales growth, as reported -0.5% Six Months Ended June 30, 2026 —
Sales growth, Constant Currency non-GAAP -1.7% Six Months Ended June 30, 2026 —
Sales growth, Organic Constant Currency non-GAAP 4.1% Six Months Ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CNMD
CONMED Corp
this stock
$1.51B +24.6% +5.2% 20.9 6.2%
ABT
Abbott Laboratories
 $187.95B -13.4% +5.7% 40.5 1.1%
MDT
Medtronic plc
 $131.57B +7.1% +8.4% 25.3 1.8%
SYK
Stryker Corp
 $117.88B -11.9% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
 $64.27B -53.5% +12.5% 18.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
270
% held
111.7%
Reported
230 of 248
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
283
View
Short & Settlement
Short Interest Falling
Shares short
1.9M
Days to cover
4.3d
Change
-51.0K sh
View
Short Volume
Short vol %
86%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
353
Value
$16.1K
As of
Oct 14, 2026
View
Off-Exchange
Off-exchange %
36.5%
Week of
Oct 5, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$1.4B
Net income (FY)
$47.1M
EPS diluted
$1.51
View
Buybacks
Authorized
$150.0M
Remaining
$112.6M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 28, 2026
This year
18

CONMED Corporation posted third-quarter sales of $335.6 million, down 0.7% year-over-year, and organic constant-currency growth of 6.7%. Diluted EPS was $0.66 and adjusted diluted EPS was $1.04; full-year sales guidance is $1,360 million–$1,366 million and adjusted diluted EPS is $4.54–$4.61.

View
Proposed Sales
Value
$10.6K
Shares
257
Filed
Nov 21, 2025
View
Earnings & Events
Webcasts
Last webcast
Oct 28, 2026
View
Investor Relations
Latest news
CONMED Corporation Reports Third…
Published
Oct 28, 2026
View

Performance

5D 20D 120D MTD YTD
CNMD -1.8% +8.3% +40.3% +14.2% +24.6%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -4.4% +9.4% +39.8% +14.4% +14.0%

Capital returns

Latest dividend
$0.20 / share · ex Sep 15, 2025
Paid (TTM)
$0.00 / share · 0 payouts
Dividend yield (TTM, derived)
— · no payout in the trailing year
Full dividend history
Buyback program · as of Mar 31, 2026
Authorized
$150.00M
Spent (derived)
$37.40M
Remaining
$112.60M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 816956 CUSIP 207410101 13F (30d) 231 filings 195 filers Visit website Investor relations